- Policy
- Green light for the reimb of Onureg, Rolontis, etc.
- by Lee, Tak-Sun Dec 19, 2022 04:35am
- A green light has been lit for the reimbursement of BMS Korea’s leukemia treatment ‘Onureg tab,’ with its agenda passing deliberations for setting reimbursement standards. Also, reimbursement standards have been prepared for 5 neutropenia treatment products including Hanmi Pharmaceutical’s Rolontis. The Health Insurance Review and Ass
- Policy
- HIRA, established a management system for high-priced drugs
- by Lee, Tak-Sun Dec 19, 2022 04:34am
- Medical institutions submit administrative information and response evaluation results to the Board of Audit and Inspection. The HIRA (Director Kim Sun-min) announced that it has been operating a "high-priced drug management system" since the 12th to increase the work efficiency of analyzing the results of response evaluations for patients r
- Policy
- Discard Moon Care Policy
- by Lee, Jeong-Hwan Dec 19, 2022 04:34am
- President Yoon Suk Yeol announced a normalization policy, emphasizing the necessity and urgency of reforming the health insurance system. Analysts say that it has virtually formalized the abolition of the policy to strengthen health insurance coverage, which is the core of the so-called "Moon Jae-in Care" promoted by the previous government.
- Policy
- MFDS approves Jemperil, the third PD-1 inhibitor in Korea
- by Lee, Hye-Kyung Dec 15, 2022 05:55am
- The Ministry of Food and Drug Safety (Director Oh Yoo-kyung) approved GlaxoSmithKline's new drug endometrial cancer treatment Jemperil on the 14th. Jemperil will be the third PD-1 inhibitor to be licensed in Korea after Opdivo of Ono and BMS and Keytgruda of MSD. Jemperil is a monoclonal antibody targeting cell predetermined history 1 (PD-1)
- Policy
- MFDS “Increasing AAP manufacturing well in progress”
- by Lee, Hye-Kyung Dec 14, 2022 05:57am
- To the issue that had been raised on how the supply shortage is continuing in the field even after increasing the price of acetaminophen, the Ministry of Food and Drug Safety replied that it has reviewed the monthly production schedule and the increase in production is progressing according to plan. Also, the MFDS added that the acetaminophen
- Policy
- $25.5 billion in exports to the health industry
- by Kim, Jung-Ju Dec 14, 2022 05:56am
- Exports of health medicine-related industries this year amounted to $25.5 billion, similar to last year, but the export of medicines such as biosimilars and vaccines was notable. The pharmaceutical sector is expected to surpass $10 billion for the first time next year based on a single item, raising expectations as a next-generation "good son ex
- Policy
- Reimb of Samil·Kukje's rebamipide eye drops adequate
- by Lee, Tak-Sun Dec 13, 2022 06:07am
- Samil Pharmaceutical and Kukje Pharma’s rebamipide eye drop solutions that were developed as a treatment for dry eye were deemed adequate for reimbursement by Korea’s Health Insurance Review and Assessment Service. This is the first achievement made for the drug in 4 months since its approval in June. With the reimbursement adequacy recog
- Policy
- Big Pharma's sale of Old Drug has increased
- by Lee, Tak-Sun Dec 13, 2022 06:07am
- The number of domestic pharmaceutical companies acquiring domestic copyrights of original drugs has been increasing recently. This is a case in which domestic copyrights have also changed as most original developers sold global copyrights as part of restructuring. Jeil announced on the 8th that it will exclusively supply Bonviva and Bonviva p
- Policy
- Will SGLT2 combi benefit expansion eventually not happen?
- by Lee, Tak-Sun Dec 12, 2022 05:48am
- iDiscussions on the expansion of combined benefits between SGLT-2 drugs and other drugs continue to conflict. The government presented a voluntary cut rate to related companies last month to analyze their fiscal impact based on it, which is known to fall short of expectations. As a result, it is expected that it will soon be decided whether to
- Policy
- “Yoon admin’s healthcare policy reduces coverage"
- by Kim, Jung-Ju Dec 9, 2022 06:03am
- "Stop deceiving the public with an erroneous essential healthcare policy that lays the responsibility for wasteful spending of commercial healthcare to the patients. Civic groups related to healthcare united and strongly voiced their opposition to the essential healthcare measures that were announced by the government. The Korean Feder
